US008563027B2

(12) **United States Patent**
Jarrett et al.

(10) **Patent No.: US 8,563,027 B2**
(45) **Date of Patent: Oct. 22, 2013**

(54) **DRUG DELIVERY THROUGH HYDROGEL PLUGS**

(71) Applicant: **Incept, LLC**, Lexington, MA (US)

(72) Inventors: **Peter Jarrett**, Lexington, MA (US); **Michael Bassett**, Pepperell, MA (US); **Charles D. Blizzard**, Westwood, MA (US); **Amarpreet S. Sawhney**, Lexington, MA (US)

(73) Assignee: **Incept, LLC**, Bedford, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/777,103**

(22) Filed: **Feb. 26, 2013**

(65) **Prior Publication Data**

US 2013/0172268 A1 Jul. 4, 2013

Related U.S. Application Data

(62) Division of application No. 12/704,692, filed on Feb. 12, 2010, now Pat. No. 8,409,606.

(60) Provisional application No. 61/152,081, filed on Feb. 12, 2009.

(51) **Int. Cl.**

A61F 2/00	(2006.01)
A01N 37/08	(2006.01)
A01N 43/42	(2006.01)
A61K 31/215	(2006.01)
A61K 31/44	(2006.01)
B29B 9/06	(2006.01)
B29C 59/00	(2006.01)

(52) **U.S. Cl.**
USPC **424/427**; 514/530; 514/300; 264/118

(58) **Field of Classification Search**
USPC 424/427; 514/530, 300; 264/118
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,161,602	A	12/1964	Herbig et al.
3,423,489	A	1/1969	Arens et al.
3,520,949	A	7/1970	Shepard et al.
3,640,741	A	2/1972	Etes
3,779,942	A	12/1973	Bolles
3,865,108	A	2/1975	Hartop
3,949,073	A	4/1976	Daniels et al.
3,949,750	A	4/1976	Freeman
3,981,303	A	9/1976	Higuchi et al.
3,991,766	A	11/1976	Schmitt et al.
3,992,562	A	11/1976	Denzinger et al.
4,002,173	A	1/1977	Manning et al.
4,014,335	A	3/1977	Arnold
4,101,380	A	7/1978	Rubinstein et al.
4,107,288	A	8/1978	Oppenheim et al.
4,141,973	A	2/1979	Balazs
4,195,129	A	3/1980	Fukui et al.
4,207,893	A	6/1980	Michaels
4,247,406	A	1/1981	Widder et al.
4,268,495	A	5/1981	Muxfeldt et al.
4,311,146	A	1/1982	Wonder
4,362,567	A	12/1982	Schwarz et al.
4,414,976	A	11/1983	Schwarz et al.
4,424,311	A	1/1984	Nagaoka et al.
4,456,711	A	6/1984	Pietsch et al.
4,472,542	A	9/1984	Nambu
4,507,466	A	3/1985	Tomalia et al.
4,530,840	A	7/1985	Tice et al.
4,532,134	A	7/1985	Malette et al.
4,568,737	A	2/1986	Tomalia et al.
4,597,970	A	7/1986	Sharma et al.
4,631,188	A	12/1986	Stoy et al.
4,646,730	A	3/1987	Schonfeld et al.
4,664,857	A	5/1987	Nambu
4,693,887	A	9/1987	Shah
4,717,378	A	1/1988	Perrault et al.
4,734,097	A	3/1988	Tanabe et al.
4,740,534	A	4/1988	Matsuda et al.
4,741,872	A	5/1988	DeLuca et al.
4,760,131	A	7/1988	Sundsmo et al.
4,803,075	A	2/1989	Wallace et al.
4,804,691	A	2/1989	English et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0732109	9/1996
EP	1967220	9/2008
WO	9425080	11/1994
WO	9705185	2/1997
WO	9719973	6/1997
WO	9722371	6/1997
WO	9739781	10/1997
WO	9812274	3/1998
WO	9835631	8/1998
WO	9903454	1/1999

(Continued)

OTHER PUBLICATIONS

Lasic et al., "Sterically Stabilized Liposomes: A Hypothesis on the Molecular Origin of the Extended Circulation Times," Biochimica et Biophysica Acta, 1070:187-192 (1991).

(Continued)

Primary Examiner — Sean Basquill
(74) *Attorney, Agent, or Firm* — Dardi & Herbert, PLLC.; Curtis B. Herbert

(57) **ABSTRACT**

An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.

31 Claims, 27 Drawing Sheets